COMPLETE-2 Study: Revascularization for Heart Attack and Multivessel Disease
This study, called COMPLETE-2, is looking at the best way to treat people who have had a heart attack (acute myocardial infarction) and also have blockages in other heart arteries (multivessel disease). Researchers are comparing two approaches to clear these extra blockages: one guided by physiology (measuring blood flow) and another guided by angiography (X-ray imaging of blood vessels). The goal is to see if the physiology-guided approach is as good as or better than the angiography-guided approach in preventing future heart problems like another heart attack or death, and if it's safer. You might be able to join if you're 18 or older, have had a specific type of heart attack, and have other blockages that can be treated. The study plans to enroll 5100 participants, but its current status is unclear.
- Study design
- This is an interventional study comparing two treatment strategies. It is a randomized controlled trial, meaning participants will be assigned to one of the two treatment groups by chance. The study plans to enroll 5100 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for at least 2 years after the study begins to track their health outcomes.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
At a glance
Conditions
Where it's being run
113 sites across 32 statesStudy leadership
- Shamir Mehta, MD · PRINCIPAL_INVESTIGATOR · Population Health Research Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Efficacy: Time to first occurrence of the composite of CV death, new MI, or IDRat study completion, a minimum of 2 years
- Safety: Time to first occurrence of the composite of clinically significant bleeding, stroke, stent thrombosis, or contrast-associated acute kidney injury.at study completion, a minimum of 2 years